Shikari® Bevacizumab Neutralizing Antibodies ELISA Kit

Bevacizumab neutralizing antibodies (NAbs) are a specific subset of anti-drug antibodies (ADAs) that develop in response to treatment with bevacizumab, a VEGF-inhibiting monoclonal antibody. Unlike non-neutralizing ADAs, which may bind to the drug without affecting its activity, NAbs directly interfere with bevacizumab’s pharmacologic function by preventing it from binding to its target, vascular endothelial growth factor (VEGF). This interaction blockade reduces or eliminates the therapeutic effect of bevacizumab, which can compromise treatment efficacy, particularly in oncology settings where consistent anti-angiogenic activity is critical.

NAbs may also cross-react with endogenous proteins, potentially causing severe physiological disruptions or immune-mediated adverse effects. Therefore, monitoring NAb development is essential during biological drug administration. Neutralizing antibody assays, such as SHIKARI® T-CAP NAb assays, are commonly used to assess this immune response. These assays detect NAb-mediated inhibition of drug-target binding, providing vital information about reduced therapeutic activity and guiding decisions on drug continuation or switching therapies.

In research and clinical practice, detecting and quantifying bevacizumab NAbs helps clinicians understand variations in patient response, identify emerging resistance, and make personalized adjustments to dosing regimens. This is particularly important in therapeutic drug monitoring (TDM), where maintaining consistent drug levels is essential. As biosimilars and biologics become more widely available, the ability to differentiate and monitor immune responses to these agents—especially NAb development—becomes increasingly important for ensuring patient safety and maximizing treatment outcomes.

This product is manufactured in Turkey by Matriks Biotek.